Australia is eagerly awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://sabrinasvbx788803.csublogs.com/50821261/this-new-drug-retatrutide-australia-a-potential-breakthrough-for-obesity-treatment